T-cell mediated RGC damage in glaucoma
T 细胞介导的青光眼 RGC 损伤
基本信息
- 批准号:10564648
- 负责人:
- 金额:$ 53.15万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-03-01 至 2027-12-31
- 项目状态:未结题
- 来源:
- 关键词:AffectAgeAllelesAnimal Disease ModelsAnimal ModelAnimalsB-LymphocytesBiological AssayBlindnessBlood specimenCD3 AntigensCD4 Positive T LymphocytesCell DeathCell FractionCessation of lifeChronicClinical ResearchCytoprotectionDataDevelopmentDiseaseExcisionExhibitsExtravasationEyeEye diseasesFrequenciesFunctional disorderFutureGene DeletionGene Expression ProfileGenetic TranscriptionGlaucomaGoalsHumanImmune responseImmunohistochemistryIndividualInflammationInflammatoryKnock-outKnockout MiceMature T-LymphocyteMediatingMedicalMethodsModelingMolecularMusPathologyPatientsPeripheral Blood Mononuclear CellPersonsPhysiologic Intraocular PressurePopulationPrimary Open Angle GlaucomaProcessProductionPublishingQuality of lifeRetinaRetinal Ganglion CellsRodent ModelRoleT cell therapyT-LymphocyteTNF geneTestingTherapeuticTimeTransgenic MiceTreatment ProtocolsVisionWorkaxonal degenerationcell injurycell mediated immune responsecell typecomparison controlcytotoxicdesignexpectationexperiencehuman diseaseimmunomodulatory therapiesimmunoregulationimprovedin vitro Assayin vivoinnovationinsightlymph nodesmouse modelmyocilinnormotensivenovelnovel therapeutic interventionperipheral bloodpreservationretinal damagesingle nucleus RNA-sequencingtranslational impact
项目摘要
Abstract:
Primary open angle glaucoma (POAG) is a potentially blinding ocular disease that affects 60
million people world-wide. Reduction of IOP is currently the only glaucoma treatment, but fails to
preserve vision in a significant fraction of patients, suggesting that other –currently untreated-
factors contribute to the disease. Therefore, there is a critical need to identify these additional
pathomechanisms to aid the development of new therapeutic approaches that directly support
survival and function of retinal ganglion cells (RGC).
Our recently published studies have demonstrated that adoptive transfer of T-cells from
glaucomatous mice into normal recipients causes RGC loss in the recipients. We have also
demonstrated that the absence of T- and B-cells profoundly protects RGC in a mouse glaucoma
model. Preliminary data included in this application demonstrates that peripheral blood
mononuclear cells (PBMC) of glaucoma patients contain a higher fraction of CD4 cells
synthesizing TNFα and exhibit a higher activation state than those of controls. We further
demonstrate that glaucoma PBMC have a heightened propensity to damage RGC in an ex vivo
assay when compared to controls. Together, these findings strongly suggest that T-cell
mediated damage is one of the mechanisms contributing to RGC loss in both animal models
and in human patients.
This project is designed with the long-term goal to determine whether modulation of immune
responses provides vision saving benefits to glaucoma patients. The objective of this application
is to establish which subtype of CD4 T-cells mediates damage in the glaucoma retina and to
determine the functional significance of CD4 cell derived TNFα. To test our novel hypothesis we
will employ a transgenic mouse model of myocilin-associated spontaneous glaucoma that we
previously developed (Tg-MYOCY437H) containing an inducible Tnf knockout allele. We have also
developed a novel in vitro assay allowing the quantitation of the cytotoxic activity of patient
PBMC targeted toward RGC. Finally we propose to determine the activities T cells extravasated
in the glaucoma retina, as well as those in lymph nodes and PBMC by establishing detailed
gene transcription profiles.
Experimental proof that CD4 T-cell mediated mechanisms contribute to vision loss in patients
would establish new targets for the medical treatment of glaucoma. These in turn will pave a
way for future clinical studies with the ultimate aim of preserving the sight and improving the
quality of life of patients with primary open angle glaucoma.
摘要:
原发性开角型青光眼是一种潜在的致盲性眼病,
全球百万人。降低IOP是目前唯一的青光眼治疗方法,但未能
在很大一部分患者中保留视力,这表明其他-目前未经治疗-
这些因素导致了这种疾病。因此,迫切需要确定这些额外的
病理机制,以帮助开发新的治疗方法,直接支持
视网膜神经节细胞(RGC)的存活和功能。
我们最近发表的研究表明,过继转移的T细胞从
正常受体中的RGC丢失。我们还
证明了T细胞和B细胞的缺乏深刻地保护了小鼠青光眼中的RGC。
模型本申请中包含的初步数据表明,外周血
青光眼患者的单个核细胞(PBMC)含有较高比例的CD 4细胞
合成TNFα,并表现出比对照组更高的活化状态。我们进一步
证明青光眼PBMC在离体培养中具有更高的损伤RGC的倾向,
与对照相比,总之,这些发现强烈表明,T细胞
介导的损伤是两种动物模型中导致RGC丢失的机制之一
和人类患者。
本项目设计的长期目标是确定是否调节免疫
这些反应为青光眼患者提供了视力挽救益处。本申请的目的
目的是确定哪种CD 4 T细胞亚型介导青光眼视网膜损伤,
确定CD 4细胞源性TNFα的功能意义。为了验证我们的新假设,
将采用一种肌球蛋白相关的自发性青光眼转基因小鼠模型,
先前开发的(Tg-MYOCY 437 H)含有可诱导的Tnf敲除等位基因。我们还
开发了一种新的体外试验,允许定量患者的细胞毒活性
PBMC靶向RGC。最后,我们建议确定T细胞外渗的活动,
在青光眼视网膜,以及淋巴结和PBMC中,通过建立详细的
基因转录谱。
实验证明CD 4 T细胞介导的机制导致患者视力丧失
将为青光眼的医学治疗建立新的目标。这反过来又会使
未来临床研究的最终目的是保护视力和改善视力。
原发性开角型青光眼患者的生活质量
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARKUS H. KUEHN其他文献
MARKUS H. KUEHN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARKUS H. KUEHN', 18)}}的其他基金
Unfolded Protein Response in Glaucoma Pathogenesis
青光眼发病机制中未折叠的蛋白质反应
- 批准号:
8542858 - 财政年份:2012
- 资助金额:
$ 53.15万 - 项目类别:
Unfolded Protein Response in Glaucoma Pathogenesis
青光眼发病机制中未折叠的蛋白质反应
- 批准号:
8370742 - 财政年份:2012
- 资助金额:
$ 53.15万 - 项目类别:
Unfolded Protein Response in Glaucoma Pathogenesis
青光眼发病机制中未折叠的蛋白质反应
- 批准号:
8720775 - 财政年份:2012
- 资助金额:
$ 53.15万 - 项目类别:
相似国自然基金
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
- 批准号:JCZRQN202500010
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
- 批准号:2025JJ70209
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
- 批准号:2023JJ50274
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
- 批准号:n/a
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
- 批准号:81973577
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
- 批准号:81602908
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
- 批准号:81501928
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341426 - 财政年份:2024
- 资助金额:
$ 53.15万 - 项目类别:
Continuing Grant
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341424 - 财政年份:2024
- 资助金额:
$ 53.15万 - 项目类别:
Continuing Grant
PROTEMO: Emotional Dynamics Of Protective Policies In An Age Of Insecurity
PROTEMO:不安全时代保护政策的情绪动态
- 批准号:
10108433 - 财政年份:2024
- 资助金额:
$ 53.15万 - 项目类别:
EU-Funded
The role of dietary and blood proteins in the prevention and development of major age-related diseases
膳食和血液蛋白在预防和发展主要与年龄相关的疾病中的作用
- 批准号:
MR/X032809/1 - 财政年份:2024
- 资助金额:
$ 53.15万 - 项目类别:
Fellowship
Atomic Anxiety in the New Nuclear Age: How Can Arms Control and Disarmament Reduce the Risk of Nuclear War?
新核时代的原子焦虑:军控与裁军如何降低核战争风险?
- 批准号:
MR/X034690/1 - 财政年份:2024
- 资助金额:
$ 53.15万 - 项目类别:
Fellowship
Walkability and health-related quality of life in Age-Friendly Cities (AFCs) across Japan and the Asia-Pacific
日本和亚太地区老年友好城市 (AFC) 的步行适宜性和与健康相关的生活质量
- 批准号:
24K13490 - 财政年份:2024
- 资助金额:
$ 53.15万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Discovering the (R)Evolution of EurAsian Steppe Metallurgy: Social and environmental impact of the Bronze Age steppes metal-driven economy
发现欧亚草原冶金的(R)演变:青铜时代草原金属驱动型经济的社会和环境影响
- 批准号:
EP/Z00022X/1 - 财政年份:2024
- 资助金额:
$ 53.15万 - 项目类别:
Research Grant
ICF: Neutrophils and cellular senescence: A vicious circle promoting age-related disease.
ICF:中性粒细胞和细胞衰老:促进与年龄相关疾病的恶性循环。
- 批准号:
MR/Y003365/1 - 财政年份:2024
- 资助金额:
$ 53.15万 - 项目类别:
Research Grant
Doctoral Dissertation Research: Effects of age of acquisition in emerging sign languages
博士论文研究:新兴手语习得年龄的影响
- 批准号:
2335955 - 财政年份:2024
- 资助金额:
$ 53.15万 - 项目类别:
Standard Grant
Shaping Competition in the Digital Age (SCiDA) - Principles, tools and institutions of digital regulation in the UK, Germany and the EU
塑造数字时代的竞争 (SCiDA) - 英国、德国和欧盟的数字监管原则、工具和机构
- 批准号:
AH/Y007549/1 - 财政年份:2024
- 资助金额:
$ 53.15万 - 项目类别:
Research Grant